FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg) April 30, 2025
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop a Multimodal Foundation Model in Oncology April 30, 2025
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers April 30, 2025
Moffitt Cancer Center Announces Strategic Collaboration With Galapagos To Transform CAR T Manufacturing in the Southeast April 30, 2025
Guardant Health and Pfizer to Develop and Commercialize New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform April 30, 2025
Sumitomo Pharma America enters into a CRADA with the NCI to Advance Clinical Understanding of Enzomenib April 22, 2025
Epsilogen Announces Acquisition of TigaTx, Inc. to Create Pan-Isotype Cancer Antibody Company April 16, 2025
Solu Therapeutics Closes $41M Series A Financing; First Patient Dosed in Ph 1 Trial of STX-0712 in Patients with CMML and Other Heme Malignancies April 16, 2025
Scancell Holdings announces partnership with the NHS CVLP to fast-track access for NHS patients into 4th cohort of Ph 2 SCOPE study April 15, 2025
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals April 15, 2025
Oncolytics Biotech Funds Pelareorep’s Development with a Share Purchase Agreement in Partnership with Alumni Capital April 15, 2025
Edity Therapeutics and Aurigene Oncology to Advance a Novel Cell Therapy Program for Solid Tumors April 8, 2025
Boehringer Ingelheim strengthens ADC portfolio with new NBE Therapeutics R&D center in Basel April 8, 2025
BORUZU, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma, launched April 8, 2025
Relmada Therapeutics Licenses Ph 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma April 2, 2025
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933 March 26, 2025
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Gen Therapeutic Antibodies March 26, 2025
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer March 26, 2025
